Kroese FGM - Search Results

1

Reduced salivary secretion contributes more to changes in the oral microbiome of patients with primary Sjögren's syndrome than underlying disease.

van der Meulen TA, Harmsen HJM, Bootsma H, Liefers SC, Vich Vila A, Zhernakova A, Weersma RK, Spijkervet FKL, Kroese FGM, Vissink A. van der Meulen TA, et al. Among authors: kroese fgm. Ann Rheum Dis. 2018 Oct;77(10):1542-1544. doi: 10.1136/annrheumdis-2018-213026. Epub 2018 Mar 23. Ann Rheum Dis. 2018. PMID: 29572289 No abstract available.

2

What have we learned from clinical trials in primary Sjögren's syndrome about pathogenesis?

Kallenberg CG, Vissink A, Kroese FG, Abdulahad WH, Bootsma H. Kallenberg CG, et al. Arthritis Res Ther. 2011 Feb 28;13(1):205. doi: 10.1186/ar3234. Arthritis Res Ther. 2011. PMID: 21371351 Free PMC article. Review.

3

Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?

Meiners PM, Vissink A, Kallenberg CG, Kroese FG, Bootsma H. Meiners PM, et al. Expert Opin Biol Ther. 2011 Oct;11(10):1381-94. doi: 10.1517/14712598.2011.605352. Epub 2011 Aug 7. Expert Opin Biol Ther. 2011. PMID: 21819314 Review.

4

Immune regulation and B-cell depletion therapy in patients with primary Sjögren's syndrome.

Abdulahad WH, Kroese FG, Vissink A, Bootsma H. Abdulahad WH, et al. J Autoimmun. 2012 Aug;39(1-2):103-11. doi: 10.1016/j.jaut.2012.01.009. Epub 2012 Feb 15. J Autoimmun. 2012. PMID: 22341852 Review.

5

How to assess treatment efficacy in Sjögren's syndrome?

Vissink A, Bootsma H, Kroese FG, Kallenberg CG. Vissink A, et al. Curr Opin Rheumatol. 2012 May;24(3):281-9. doi: 10.1097/BOR.0b013e3283524c37. Curr Opin Rheumatol. 2012. PMID: 22450393 Review.

6

Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy.

Hamza N, Bootsma H, Yuvaraj S, Spijkervet FK, Haacke EA, Pollard RP, Visser A, Vissink A, Kallenberg CG, Kroese FG, Bos NA. Hamza N, et al. Ann Rheum Dis. 2012 Nov;71(11):1881-7. doi: 10.1136/annrheumdis-2011-201189. Epub 2012 May 21. Ann Rheum Dis. 2012. PMID: 22615459

7

Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial.

Pollard RP, Abdulahad WH, Vissink A, Hamza N, Burgerhof JG, Meijer JM, Visser A, Huitema MG, Spijkervet FK, Kallenberg CG, Bootsma H, Kroese FG. Pollard RP, et al. Ann Rheum Dis. 2013 Jan;72(1):146-8. doi: 10.1136/annrheumdis-2012-202071. Epub 2012 Jul 31. Ann Rheum Dis. 2013. PMID: 22851468 Clinical Trial. No abstract available.

8

Systems analysis of primary Sjögren's syndrome pathogenesis in salivary glands identifies shared pathways in human and a mouse model.

Horvath S, Nazmul-Hossain AN, Pollard RP, Kroese FG, Vissink A, Kallenberg CG, Spijkervet FK, Bootsma H, Michie SA, Gorr SU, Peck AB, Cai C, Zhou H, Wong DT. Horvath S, et al. Arthritis Res Ther. 2012 Nov 1;14(6):R238. doi: 10.1186/ar4081. Arthritis Res Ther. 2012. PMID: 23116360 Free PMC article.

9

Sjögren's syndrome in older patients: aetiology, diagnosis and management.

Moerman RV, Bootsma H, Kroese FG, Vissink A. Moerman RV, et al. Drugs Aging. 2013 Mar;30(3):137-53. doi: 10.1007/s40266-013-0050-7. Drugs Aging. 2013. PMID: 23341116 Review.

10

Biomarkers: new biomarker for Sjögren's syndrome--time to treat patients.

Kroese FG, Bootsma H. Kroese FG, et al. Nat Rev Rheumatol. 2013 Oct;9(10):570-2. doi: 10.1038/nrrheum.2013.143. Epub 2013 Sep 17. Nat Rev Rheumatol. 2013. PMID: 24045708 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

162 results

Search Page

Filters